Barclays PLC Raises Stock Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Barclays PLC boosted its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 21.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 46,396 shares of the company’s stock after purchasing an additional 8,178 shares during the quarter. Barclays PLC owned about 0.09% of Mineralys Therapeutics worth $571,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MLYS. China Universal Asset Management Co. Ltd. grew its stake in shares of Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after purchasing an additional 989 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth $154,000. AlphaQuest LLC increased its stake in Mineralys Therapeutics by 2,637.8% in the 4th quarter. AlphaQuest LLC now owns 15,222 shares of the company’s stock valued at $187,000 after buying an additional 14,666 shares during the period. SG Americas Securities LLC raised its position in Mineralys Therapeutics by 119.0% during the 4th quarter. SG Americas Securities LLC now owns 19,961 shares of the company’s stock worth $246,000 after buying an additional 10,845 shares during the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in Mineralys Therapeutics during the 4th quarter worth $285,000. Institutional investors and hedge funds own 84.46% of the company’s stock.

Mineralys Therapeutics Trading Up 5.8 %

Shares of MLYS opened at $15.61 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The firm has a market capitalization of $1.01 billion, a P/E ratio of -4.29 and a beta of -0.30. The firm’s 50-day moving average is $13.89 and its two-hundred day moving average is $12.42.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its earnings results on Wednesday, February 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. Analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 15,319 shares of the firm’s stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $12.19, for a total transaction of $186,738.61. Following the sale, the chief executive officer now owns 862,289 shares in the company, valued at approximately $10,511,302.91. This trade represents a 1.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Malcom Rodman sold 55,771 shares of the business’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $15.76, for a total value of $878,950.96. Following the completion of the transaction, the insider now owns 116,704 shares of the company’s stock, valued at $1,839,255.04. This trade represents a 32.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 93,213 shares of company stock worth $1,360,567. 25.56% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on MLYS shares. HC Wainwright boosted their price target on shares of Mineralys Therapeutics from $30.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, April 2nd. Guggenheim reissued a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, February 24th. Finally, The Goldman Sachs Group decreased their price target on Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.